1. Gaithersburg Biotech Seals Deal With Johnson & Johnson
Emergent BioSolutions (NYSE:EBS) previously announced deal with Johnson & Johnson’s (NYSE: JNJ) Janseen Pharma unit has been solidified. The five-year agreement for COVID-19 vaccine manufacturing is valued at more than $480 million
2. Gaithersburg’s Emergent BioSolutions Partners For Their Own COVID-19 Vaccine
Emergent BioSolutions (NYSE: EBS), The Mount Sinai Health System, and ImmunoTek Bio Centers have formed a partnership to develop, manufacture, and conduct clinical trials to evaluate Emergent’s COVID-19 hyperimmune globulin product called COVID-HIG. Hyperimmune globulin is collected from donors and contain concentrated antibodies. The collaboration is backed by $34.6 million in funding from the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND).Trials will be conducted in the epicenter of COVID-19 cases and deaths in New York City.
3. Regenxbio shows promising data on Nervous System and Spinal Cord Drug
A drug to treat a disease that affects the brain, nervous system and spinal cord show promise accroding to data from Rockville-based Regenxbio. The treatment of Mucopolysaccharidosis Type II (MPS II) was observed in patients during a phase I/II study. They were dosed with Regenxbio’s drug called RGX-121. Regenxbio will be moving into one of the largest life science buildings underway in the D.C. area. The building along Shady Grove Road will be fully-leased to Regenxbio and will become their new headquarters.
4. Gaithersburg Biotech Partners with Austria Firm To Battle Tumors
Gaithersburg-based MaxCyte has partnered with Vienna, Austria-based Apeiron to fight cancerous solid tumors. Apeiron signed a non-exclusive agreement to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to advance Apeiron’s APN401 drug noted as a siRNA-based cell therapy.